On June 14th, 2013, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended to suspend the marketing authorization of all HES products in Europe. FDA followed few days later. A clinical benefit of using HES could not be demonstrated in any patient population according to 3 megatrials (VISEP, 6S, CHEST), and there is evidence of increased incidence of renal failure. Follow @anestesiaISVRA on Twitter for more details on this topic.
